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Abstract
Background: To compare and evaluate the possible advantages related to the use of VMAT and helical IMRT and
two different modalities of boost delivering, adjuvant stereotactic boost (SRS) or simultaneous integrated boost
(SIB), in the treatment of brain metastasis (BM) in RPA classes I-II patients.
Methods: Ten patients were treated with helical IMRT, 5 of them with SRS after whole brain radiotherapy (WBRT)
and 5 with SIB. MRI co-registration with planning CT was mandatory and prescribed doses were 30 Gy in 10
fractions (fr) for WBRT and 15Gy/1fr or 45Gy/10fr in SRS or SIB, respectively. For each patient, 4 “treatment plans”
(VMAT SRS and SIB, helical IMRT SRS and SIB) were calculated and accepted if PTV boost was included in 95 %
isodose and dose constraints of the main organs at risk were respected without major deviations. Homogeneity
Index (HI), Conformal Index (CI) and Conformal Number (CN) were considered to compare the different plans.
Moreover, time of treatment delivery was calculated and considered in the analysis.
Results: Volume of brain metastasis ranged between 1.43 and 51.01 cc (mean 12.89 ± 6.37 ml) and 3 patients had
double lesions. V95% resulted over 95 % in the average for each kind of technique, but the “target coverage” was
inadequate for VMAT planning with two sites. The HI resulted close to the ideal value of zero in all cases; VMAT-SIB,
VMAT-SRS, Helical IMRT-SIB and Helical IMRT-SRS showed mean CI of 2.15, 2.10, 2.44 and 1.66, respectively (optimal
range: 1.5–2.0). Helical IMRT-SRS was related to the best and reliable finding of CN (0.66). The mean of treatment
time was 210 s, 467 s, 440 s, 1598 s, respectively, for VMAT-SIB, VMAT-SRS, Helical IMRT-SIB and Helical IMRT-SRS.
Conclusions: This dosimetric comparison show that helical IMRT obtain better target coverage and respect of
CI and CN; VMAT could be acceptable in solitary metastasis. SIB modality can be considered as a good choice for
clinical and logistic compliance; literature’s preliminary data are confirming also a radiobiological benefit for SIB.
Helical IMRT-SRS seems less effective for the long time of treatment compared to other techniques.
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Background
Brain metastases occur in 30 % of all patients with
cancer [1] and the incidence is increasing in relation to
the improvement of local control and survival related to
new available systemic treatments and to the inability of
most drugs to cross the blood brain barrier. Moreover,
in Italy, the aging of the population and the better
diagnostic accuracy obtained with Magnetic Resonance
(MRI) contribute to the increase in frequency of BM
diagnosis [2, 3].
The main prognostic factors for patients with BM are
the Karnofski Performance Status (KPS) (≥70 or < 70),
age (<65 or ≥ 65), controlled primary site and the pres-
ence of extra cranial metastasis according to the Recur-
sive Partitioning Analysis (RPA) [4, 5]. Recently, a
Graded Prognostic Analysis (GPA) has been introduced
in order to consider the histology of the primary tumour
to the already known prognostic factors [6–8].
To date, the possible therapeutic approaches to BM are
surgery (SUR) [9, 10], whole brain radiotherapy (WBRT)
[11] and stereotactic radiosurgery (SRS) alone or in com-
bination [7, 12]. Median overall survival (OS) is 1–2
month with supportive care [13], while after WBRT is 7.1,
4.2, 2.3 respectively for RPA class I, II, III [4]. More ag-
gressive treatments as SUR or SRS alone or combined to
WBRTcan double OS rates [14] with an acceptable neuro-
toxicity and quality of life [15–17]. A careful patients se-
lection remains crucial to identify who really benefits of
intensified local treatments.
To date, it is widely debated if the linear quadratic
(LQ) model is able to predict the biological effects of
high fractional doses used for stereotactic treatment in
BM. Kirkpatrick suggests that tumour control probability
after a single stereotactic fraction is higher than expected
according to the quadratic linear model [18]. On the con-
trary, Brenner argues that the LQ model is theoretically
and experimentally validated up to a single fraction dose
of 10 Gy [19]. Recently, it has been hypothesized that the
introduction in the formalism of a parameter propor-
tional to the cube of the dose (linear quadratic cubic -
or LQC- model), could result in a better fitting of the
resulting dose - local control curve with the clinical
data [20]. A revision of 11 studies on SRS in BM has
shown a good correlation between the local control rate at
12 months and the biological equivalent dose (α/β 12 Gy),
calculated with the LQC model, for fractional doses ranging
between 6 and 25 Gy; the analysis concluded suggesting ex-
cellent local control rates at 12 months after single-fraction
doses higher than 20 Gy as opposed to clearly insufficient
results for doses lower than 15 Gy [21].
Some authors suggest that this approach does not allow
to exploit all the potential benefits of fractionation in
terms of radiobiological redistribution and re-oxygenation.
Hall et al. argue that fractionated stereotactic treatments
may be more effective than those in single fraction [22]. In
addition, tumour cell repopulation and repair of sub-lethal
damage may occur when a significant interval between
WBRT and SRS is provided [23]. Finally, SRS treatments
may require very long treatment sessions, possibly forcing
to split them in multiple sessions.
From a dosimetric point of view, the possibility of
incorporating the contribution of the boost in larger vol-
umes treated with lower doses is a definite advantage of the
simultaneous integrated boost (SIB) compared to SRS [24].
In fact, the stereotactic boost after WBRT adds an uninten-
tional dose to the brain, while SIB technique makes pos-
sible to optimize the dose distribution taking into account
WBRT and boost simultaneously [25, 26]. Both volumetric
modulated arc therapy (VMAT) and helical IMRT are able
to deliver high radiation doses to the target with excellent
precision, thus preserving organs at risk. Although it is not
completely clear how SRS and SIB could be considered
biologically equivalent due to the possible limits of
applicability of LQ model, a comparative dosimetric and
technical analysis of ten cases has been performed, in
order to assess benefits or drawbacks of SRS vs SIB and
Helical IMRT vs VMAT in terms of cost-effectiveness and
appropriateness of different therapeutic techniques.
Methods
Ten patients with BM in RPA prognostic class I-II were
considered for this analysis (in particular 5 with SRS and
5 with SIB). They were selected among the first patients
treated with helical IMRT at our Department, in order
to identify technical and dosimetric variables relevant in
the treatment of BM with stereotactic approach and to
compare helical IMRT with VMAT in this clinical
setting. All patients had one BM but three of them who
had two lesions. Five were treated with SRS after WBRT
and the remaining 5 with SIB. SIB was preferred when
MRI was available at planning, while SRS boost was
postponed after WBRT in order to have MRI to confirm
number and dimension of BM. All patients were treated
with Helical IMRT. Precautionary dose of 15 Gy as SRS
boost and 45 Gy as SIB were prescribed for these cases
because they were the first patients treated in this way
in our department.
Patients were simulated in supine position using a CT
scan (3 mm slice thickness and spacing) over the entire
head region; thermoplastic masks were used to immobilize
the patients. CT images were co-registered through a rigid
protocol with diagnostic MRI (axial T1-weighted gado-
linium contrast enhancement sequences).
The whole brain was contoured and considered as WB-
CTV; different gross tumor volumes were defined for each
metastasis as the contrast enhanced lesion; 5 mm radial
and 6 mm cranio-caudal expansion was applied to
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obtain WB-PTV and 3 mm isotropic expansion to
obtain boost-PTV.
Organs at risk (OAR) included eyes, lens, optic nerves,
chiasm, brainstem and brain parenchyma (excluding BM).
A Helical IMRT dedicated treatment planning system
(TPS) and the Pinnacle® V9.2 TPS were respectively used
for Helical IMRT and VMAT plans.
VMAT plans were generated for an Elekta Synergy linear
accelerator equipped with 1 cm at isocenter MLC. Two or
more modulated arcs of 10 MV nominal energy photons
beams with maximum dose rate of 600 U.M./min were
used (number of arcs used for SRS and SIB VMAT plans
are reported in Table 2). Computing grid was of 2 × 2 ×
3 mm3. Helical IMRT plans employed the standard nom-
inal energy 6 MV photons beams with either 1.05 cm field
width or 2.5 cm field width for SRS boost and SIB respect-
ively. Pitch value was defined 0.1 for SRS and 0.278 for
concomitant boost plans. A modulation factor of 2.0 and a
computing grid of 1.95 × 1.95 × 3 mm3 (fine calculation)
were chosen for optimization process and final dose
calculation for both the SRS boost and the SIB. All
VMAT plans were coplanar with a single isocenter,
even for two lesions ones.
All plans were elaborated by the same planner either
for VMAT and Helical IMRT and all of them were
re-planned by a second independent expert planner in
order to ensure optimization.
For each of the 10 cases, 4 treatment plans were calcu-
lated and optimized (one of them was actually delivered).
Plan 1: WBRT (30 Gy/10 fr) followed by SRS boost
(15 Gy/1 fr) with Helical IMRT technique
Plan 2: WBRT (30 Gy/10 fr) with SIB up to 45 Gy/10 fr
with Helical IMRT technique
Plan 3: WBRT (30 Gy/10 fr) followed by SRS boost
(15 Gy/1 fr) with VMAT technique
Plan 4: WBRT (30 Gy/10 fr) with SIB up to 45 Gy/10 fr
with VMAT technique.
In the treatment plans with sequential boost, WBRT
was provided using two 6MV opposing lateral fields
equally balanced. In these cases Helical IMRT and VMAT
were used exclusively for the boost. The dosimetric assess-
ment of the organs at risk was performed considering the
sum of the doses delivered in the two separate plans
(WBRT + SRS boost). Regarding SIB plans, instead, the
helical and volumetric techniques were used for the over-
all plan, to include whole brain and BM. All plans were
elaborated in order to obtain the best potentially
deliverable plan for an acceptable target coverage,
without violations of dose constraints to OAR.
Statistical analysis
Doses to WB-PTV and boost-PTV were prescribed to
100 % according to the criteria of the International
Commission on Radiation Units & Measurements (ICRU).
The minimum accepted dose to PTV brain and PTV
boost was 95 % of the prescribed dose. None maximum
dose limit to PTV boost was established, although it was
normally within the 108 % of the prescribed dose.
The doses to the organs at risk were evaluated
considering dose-constraints reported in the literature
[25–27] (Table 1). Dose constraint to brain without
PTV (V12Gy <10 ml) was considered just for the single
dose of SRS boost.
Doses at 1 ml (D1ml), 2 % (D2), 5 % (D5), 50 % (D50),
95 % (D95), 98 % (D98), 99 % (D99) and the mean dose
to the target volume (Davg) and the volumes to 95 %
(V95), 99 % (V99) and 108 % (V108) of the prescribed
dose were used for the dosimetric evaluation of PTV
boost SRS and SIB.
In order to evaluate homogeneity of the dose distribu-
tion and the dose conformity, according to the require-
ments of ICRU 62 [28], three parameters were analysed:
– Homogeneity Index (HI) is an objective tool
to analyse the uniformity of dose distribution
in the target volume. Various formulae have
been described in literature for its calculation and
the more descriptive formula is HI = (D2-D98)/Dp,
where D2 =minimum dose to 2 % of the
target volume indicating the “maximum dose”,
D98 =minimum dose to the 98 % of the target
volume, indicating the “minimum dose” and
Dp = prescribed dose. This is the most commonly
used formula in the literature. The reason for
choosing D98 and D2, to represent the minimum
and maximum dose, is that the calculation of true
minimum or maximum dose is sensitive to the
dose-calculation parameters, such as grid size and
grid placement, and the high dose gradient is
common in Intensity Modulated Radio-Therapy
[29]. HI basically indicates the ratio between the
maximum and minimum dose in the target volume
and the lower value indicates a more homogenous
dose distribution within this volume. Smaller HI
values indicate more homogeneous dose distributions
and the optimal value is to be close to 0.
Table 1 Organ at risk dose constraints used for treatment plans
Organ at risk Dose constraints
SIB SRS
Brain (without PTV) Dmean ≤ 32 GyV35 Gy < 15 %
V40 Gy < 5 % V45 Gy < 0 %
V12Gy < 10 cc
Brainstem Dmax < 35Gy Excluded
Chiasm Dmax < 35Gy Excluded
Optic nerve Dmax < 35Gy Excluded
Lens Dmax < 5 Gy Dmax < 5 Gy
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– Conformity Index (CI), defined as the ratio between
the total volume enclosed in the references isodose
(VRI) and target volume (TV) (CI = VRI/TV)
[29, 30]. This index shows the target coverage
related to a specific reference isodose (RI)
considered as a reasonable limit of acceptability of
the treatment plan, in this case the 95 % isodose. If
the conformity index is situated between 1 and 2,
the treatment is considered to comply with the
treatment plan; an index between 2 and 2.5, or 0.9
and 1, is considered to be a minor violation, and
when the index value is less than 0.9 or exceeds 2.5,
the protocol violation is considered to be major, but
may nevertheless be considered to be acceptable.
– Conformation Number (CN) is defined as in the next
formula: (PTVpi/Vpi) × (PTVpi/PTV), where PTVpi
is the target volume which is irradiated with
prescription isodose (pi) and Vpi is the total volume
of tissue which is irradiated with prescription
isodose [29]. The values of this index can range
between 0 and 1; it is usually considered optimal if
close to 1, but values between 0.5 and 0.7 can also
be considered satisfactory.
Finally, time of treatment delivery for each planning
was calculated.
The statistical analysis was performed using t-Student
test for the comparison of the PTV Boost, HI, CI, CN
and time of treatment values. The differences were con-
sidered statistically significant if p < 0.05.
Results
Ten patients were considered for the analysis; for a total
number of 13 BM, 52 PTV boost were calculated. The
site of disease were cortical lobes, cerebellum and deep
structures respectively in 10, 1 and 2 BM. Mean WB-PTV
was 1631 cc (range 1275–1899 cc) and mean boost-PTV
was 14.32 cc (range 1.43–51 cc). More data are shown in
Table 2.
Dose constraints to the OAR evaluated (chiasm, brain-
stem, right and left lens, right and left optic nerve) were
all respected without major violations.
In the SRS cases there was no statistical difference be-
tween VMAT and Helical IMRT in terms of respect of
OAR, considering that they received the dose due to
WBRT and they were basically excluded by the dose
contribute of stereotactic boost. In the SIB cases, the
OAR were generally better respected in terms of Dmax,
particularly for chiasm (30.31 Gy vs 32.36 Gy; p = 0.002)
and brainstem (30.95 Gy vs 33.11 Gy; p = 0.013) with
Helical IMRT-SIB compared to VMAT-SIB.
The Brain excluded from the PTV volume (Brain-PTV)
appear the most critical OAR:
– In the SIB cases there were no major violations
in terms of Dmax <32Gy (31.15Gy and 30.96Gy
respectively for Helical IMRT and VMAT),
V35 < 15Gy (7.65Gy and 4.32Gy respectively),
V40 < 5 Gy (3.08Gy and 1.37Gy respectively)
and V45 < 0 Gy (0.02Gy and 0.11Gy respectively),
without statistically significant differences between
the techniques;
– In the SRS cases Brain-PTV exceeded the dose
constraints (V12 Gy < 10 ml) in all VMAT-SRS
plans (mean 34.10 ml) and in 4 Helical IMRT-SRS
plans (mean 9.27 ml), with a statistically
significant benefit for Helical IMRT-SRS
(p = 0.019).
All but six (95 %) of the PTV boosts volumes received
at least 95 % of the prescribed dose. The six plans that
resulted in inadequate target coverage had been calcu-
lated as VMAT-SIB, VMAT-SRS and Helical IMRT-SRS
in two cases each respectively. In particular, five of them
referred to patients with two BM. Nevertheless, the
mean of VPTVboost95% was over 95 % of prescribed dose
for each kind of calculated plans, without statistically
significant differences (Table 3).
The analysis of dosimetric parameters for SRS plans
showed that HI was 0.07 for both the techniques (very
close to the optimal), CI resulted acceptable in VMAT
plans (2.1) and optimal in Helical IMRT ones (1.66)
without significant differences. CN appeared better for
Helical IMRT than for VMAT (0.66 vs 0.49 – p = 0,067)
(Table 3).
Regarding SIB plans, HI was 0.03 and 0.08 for Helical
IMRT and VMAT respectively (p < 0.001), no relevant
differences emerged for CI and CN, that resulted within
an acceptable range (Table 4).
Time of treatment delivery was significantly longer
in Helical IMRT plans (either SRS and SIB, Tables 3
and 4). Helical IMRT-SRS fractions lasted 3 times longer
than the VMAT SRS ones (1598 s vs 468 s, p < 0.001). SIB
plans were faster to deliver than the SRS ones but
still Helical IMRT lasted twice as long (440 s vs
210 s, p = 0.004).
Discussion
The efficacy and feasibility of a stereotactic boost associ-
ated with WBRT has been shown in two randomized
clinical trials. In the RTOG 9508 trial [12] 333 patients
with 1–3 brain metastases were randomly allocated to
either WBRT or SRT-WBRT: WBRT and stereotactic
boost treatment improved functional autonomy for all
patients and survival for patients with a single metasta-
sis. In the secondary analysis performed after 10 years
252 patients have been re-classified according to the
GPA scale and re-analyzed. Survival advantage was
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Table 2 Characteristics of cases
pt 1 pt 2 pt 3 pt 4 pt 5 pt 6 pt 7 pt 8 pt 9 pt 10
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Whole brain PTV (ml) 1796.12 1899.90 1440.29 1573.23 1581.73 1554.60 1769.70 1840.10 1583.20 1275.46
Diameter max. of
metastasis (mm)
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35 8 11
Boost PTV (ml) 10.75 7.25 15.23 13.68 11.01 5.77 21.88 12.10 5.28 25.92
51.01 1.43 4.79
Number of arcs - SIB 2 3 2 2 2 2 2 4 2 6










found only in patients with high GPA score (3.5-4) regard-
less of whether they have 1, 2, or 3 brain metastases. A
smaller trial [31] showed that the combination of WBRT
and radiosurgery for patients with two to four brain me-
tastases significantly improves control of brain disease,
without improvement of survival. Logistically, radiosur-
gery requires separate localization and treatment proce-
dures that add some inconvenience and cost for patients,
providers and caregivers. Single fraction treatments also
do not permit the exploitation of the potential radiobio-
logic benefits of re-assortment and re-oxygenation that
may occur with a fractionated radiotherapy course. Hall et
al. [22] have argued that fractionated stereotactic radio-
therapy may be more efficacious in the treatment of neo-
plastic disease compared to single fraction radiosurgery.
Additionally, tumour cell repopulation or sub-lethal dam-
age repair may occur if there is a significant break between
the radiosurgery and whole brain radiotherapy sessions.
Finally, depending on the radiosurgery system used, treat-
ment of more than 3 metastases may involve prohibitively
long treatments, requiring multiple sessions or omission of
radiosurgery entirely. The introduction of in-room image
guidance systems integrated with radiation treatment
machines has led to the introduction of non-invasive
stereotactic radiosurgery/radiotherapy techniques. One
such unit, Helical IMRT combines intensity modulated
fan-beam radiotherapy delivery with megavoltage com-
puted tomography (MVCT) imaging for integrated patient
positioning and treatment delivery [32, 33]. From a dosi-
metric point, the ability to incorporate boost contributions
Table 3 Dosimetric parameters of SRS plans
Technique PTV Brain-PTV CI HI CN Time
(seconds)Patient D95% (Gy)/% V12Gy (ml)
1 Helical IMRT-SRS 14.5/96.7 9.0 2.22 0.06 0.70 1150
VMAT-SRS 14.7/98.3 0.00 2.29 0.07 0.50 386
2 Helical IMRT-SRS 13.9/92.7 6.9 1.17 0.11 0.65 1266
VMAT-SRS 14.8/98.5 36.3 3.07 0.03 0.30 419
3 Helical IMRT-SRS 14.8/98.3 10.7 1.25 0.22 0.80 1188
VMAT-SRS 14.7/97.7 58.6 3.28 0.03 0.06 375
4 Helical IMRT-SRS A 14.9/99.3 36.2 5.54 0.04 2.53 2712
Helical IMRT-SRS B 14.6/96.7 1.11 0.06 0.51
VMAT-SRS A 15.5/103.3 13.8 1.42 0.12 1.21 543
VMAT-SRS B 15.5/103.3 1.12 0.13 0.90
5 Helical IMRT-SRS 14.8/98.7 16.4 1.48 0.04 0.46 1222
VMAT-SRS 15.0/100 87.8 0.09 0.02 0.51 578
6 Helical IMRT-SRS 14.8/98.9 10.5 1.56 0.04 0.47 1051
VMAT-SRS 15.0/100 59.6 6.67 0.06 0.36 549
7 Helical IMRT-SRS 14.9/99.0 1.2 1.26 0.03 0.51 1314
VMAT-SRS 14.7/97.7 26.0 1.35 0.03 0.42 425
8 Helical IMRT-SRS A 13.7/91.0 0.50 1.00 0.13 0.27 2112
Helical IMRT-SRS B 14.7/98.1 1.54 0.03 0.42
VMAT-SRS A 14.4/96.0 16.5 1.26 0.07 0.41 571
VMAT-SRS B 14.5/96.7 1.70 0.04 0.44
9 Helical IMRT -SRS 14.9/99.5 0.54 1.57 0.01 0.37 1182
VMAT-SRS 14.8/98.5 25.1 3.00 0.01 0.33 403
10 Helical IMRT-SRS A 14.5/96.3 0.87 1.20 0.08 0.48 2784
Helical IMRT-SRS B 14.3/95.1 0.69 0.09 0.38
VMAT-SRS A 14.0/93.3 17.4 1.10 0.13 0.34 427
VMAT-SRS B 14.0/93.3 0.90 0.12 0.41
Helical IMRT-SRS (mean) 14.55 9.27 1.66 0.07 0.66 1598.10
VMAT-SRS(mean) 14.73 34.10 2.10 0.07 0.49 467.60
p (T student) ns 0.019 ns ns ns 0.000
Legend: Patients number 4, 8 and 10 had two brain metastases, volume and the dosimetric parameters of each lesion (A and B) are reported in the table
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with larger field volumes as part of the treatment planning
optimization process provides an advantage of the sim-
ultaneous boost strategy over sequential whole brain
radiotherapy with radiosurgery boost. This advantage
occurs as the radiosurgery boost dose is added to the
previously delivered whole brain dose without oppor-
tunity for optimization of these two components; the
need for two different plans potentially results in unin-
tended increased dose to the brain [34].
In the literature there are numerous studies, in which
the use of SIB for the treatment of brain metastases was
proposed with different techniques. They are all feasibility
studies and, sometimes, dose escalation studies with the
aim of reaching doses comparable to those of sequential
SRS, according to the linear quadratic cube (LQC) model
[20]. The first study was published by Bauman et al. in
2007 [25]: fourteen patients underwent radiotherapy in
10 fraction, 60 Gy on the lesions and 30 Gy on whole
brain. They choosed this regimen since the dose of
60 Gy in 10 fractions was equated to 18 Gy in single
fraction through the LQC model. The comparison to
conventional non-coplanar arc fractionated stereotactic
radiotherapy plan demonstrated similar target coverage
and improved critical tissue sparing even for a challen-
ging anatomy with multiple lesions in the same plane
as the optic apparatus. The Authors concluded that the
approach with Helical IMRT has potential advantages
such as frameless stereotactic localization through daily
megavoltage computed tomography, more efficient use of
resources and exploitation of radiobiologic advantages of
Table 4 Dosimetric parameters of SIB plans
Technique PTV Brain-PTV CI HI CN Time
(seconds)Patient D95% (Gy)/% Dmean (Gy) V35 (%) V40 (%) V45 (%)
1 Helical IMRT-SIB 44.4/98.6 30.6 2.4 0.85 0.00 1.61 0.02 0.31 980
VMAT-SIB 44.3/98.4 31.5 3.0 1.03 0.04 1.83 0.07 0.67 277
2 Helical IMRT-SIB 44.8/99.6 31.5 12.6 5.9 0.13 4.79 0.02 0.49 247
VMAT-SIB 45.1/100.3 31.3 3.6 1.14 0.10 2.12 0.09 0.74 193
3 Helical IMRT-SIB 43.9/97.6 31.2 14.4 5.4 0.00 2.09 0.04 0.27 409
VMAT-SIB 42.8/95.0 29.8 3.4 0.83 0.01 1.11 0.16 0.68 168
4 Helical IMRT-SIB A 43.5/96.6 31.8 10.7 3.4 0.00 6.03 0.05 2.00 480
Helical IMRT-SIB B 43.4/96.5 0.36 0.06 0.07
VMAT-SIB A 43.6/96.8 32.3 16.9 5.6 0.79 8.06 0.13 3.13 195
VMAT-SIB B 44.9/99.7 1.68 0.12 0.71
5 Helical IMRT-SIB 44.6/99.1 31.4 4.3 1.55 0.00 1.83 0.02 0.46 485
VMAT-SIB 44.9/99.8 31.9 3.6 1.34 0.07 3.84 0.06 0.22 237
6 Helical IMRT-SIB 44.2/98.3 31.3 4.0 0.93 0.00 1.69 0.04 0.41 401
VMAT-SIB 44.9/99.7 31.0 2.6 1.06 0.06 2.08 0.05 0.73 235
7 Helical IMRT-SIB 44.2/98.2 30.5 3.3 1.00 0.00 1.38 0.03 0.34 276
VMAT-SIB 43.1/95.8 31.3 2.8 0.90 0.00 1.11 0.05 0.00 247
8 Helical IMRT-SIB A 43.8/97.3 31.6 13.6 6.9 0.05 1.77 0.05 0.49 366
Helical IMRT-SIB B 44.4/98.6 3.57 0.02 0.28
VMAT-SIB A 42.3/94.0 29.9 3.5 0.80 0.00 1.11 0.07 0.02 149
VMAT-SIB B 43.3/96.1 1.58 0.04 0.01
9 VMAT-SIB 43.3/99.3 30.3 1.5 0.50 0.00 1.19 0.05 0.15 133
Helical IMRT-SIB 44.7/96.1 30.5 3.0 1.30 0.01 2.45 0.02 0.61 372
10 Helical IMRT-SIB A 44.7/99.3 31.0 8.2 3.6 0.00 2.12 0.02 0.54 384
Helical IMRT-SIB B 44.5/98.9 1.98 0.03 0.49
VMAT-SIB A 40.9/90.9 30.4 2.4 0.45 0.00 0.98 0.12 0.15 267
VMAT-SIB B 43.3/96.3 1.32 0.05 0.15
Helical IMRT-SIB (mean) 44.24 31.15 7.65 3.08 0.02 2.44 0.03 0.52 440.00
VMAT-SIB(mean) 43.57 30.96 4.32 1.37 0.11 2.15 0.08 0.57 210.10
p T student ns ns ns ns ns ns 0.000 ns 0.004
Legend: Patients number 4, 8 and 10 had two brain metastases, volume and the dosimetric parameters of each lesion (A and B) are reported in the table
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fractionation. After that other Authors have proposed
different fractionation regimes: Weber [34] judged well-
tolerated treatments with VMAT in 10 fractions (30 Gy
and 40 Gy on whole brain and on metastatic lesions, re-
spectively); Rodrigues [35] confirmed the data of Bauman
[25] with 60 Gy in 10 fr on metastases with Helical IMRT,
after a dose-escalation study from 35 to 60 Gy in 10 fr;
Zhou [36] proposed WBRT in 20 fr with a total dose of
40 Gy and during the last week of treatment a simul-
taneous boost on brain metastases of 20 Gy in 5 fr with
IMRT-IGRT.
The sparing of hippocampal areas, during WBRT with
volumetric techniques, had already been studied by Gondi
[37] in 2010, with the aim of reducing the impact of
WBRT on cognitive functions of long-term survivors pa-
tients. Recently the use of the SIB with hippocampal spar-
ing has been the object of a greater interest; the aim is to
boost the site of disease without interfering with the neu-
rocognitive functions [38, 39].
In literature dosimetric comparison trials were not
published. With the drawbacks of a limited sample size,
our work is therefore the first dosimetric comparative
study between techniques (Helical IMRT vs VMAT) and
boost delivering modality (SRS vs SIB). Although the
number of cases of the present series does not allow to
draw clinically sound conclusions, the choice of using a
panel of descriptors including conformal index, con-
formal number and homogeneity index has been made
to obtain a synthetic evaluation all the dosimetric issues
potentially influential for the cost/benefit ratio of the
treatments delivered with the different techniques.
Only one trial has already made a comparison between
the different modality of boost administration. Rodrigues
et al. [40] in 2013 published a retrospective review of
500 patients treated with SRS alone or SIB-WBRT: no
differences in OS were found but SIB was associated
with a reduced intracranial failure rate likely due to the
WBRT component of the treatment; however, SRS pa-
tients did not have WBRT, at variance with the present
series. No dosimetric comparison was performed.
Conclusions
Although limited and preliminary, this series shows that
SRS or SIB BM treatments are feasible with both Helical
IMRT and VMAT techniques. A notable dosimetric ad-
vantage emerged for Helical IMRT plans, in particular to
reduce the normal brain irradiated volume (Brain-PTV)
in SRS and other critical organs, such as chiasm and
brainstem, in SIB. These clinical findings cannot be gener-
alized due to the exiguous number of cases and heteroge-
neous locations of lesions. No relevant differences were
evident for PTV boost coverage, although VMAT plans
are more frequently not optimal, in particular for cases
with two BM. Mild discrepancies were presented in terms
of dosimetric parameters (slightly in favour of Helical
IMRT plans, especially for HI). This assessment may be
due to the intrinsic characteristics of Helical IMRT. In this
regard is useful to note that the width of MLC leaves is
smaller in Helical IMRT machine than in the Linac used
(0.6 cm vs 1 cm) and this contributes to increase dose
conformation to the target.
A longer treatment delivery time resulted the more im-
portant intrinsic limit of Helical IMRT. Too long treatment
times should be avoided in order to reduce intrafraction
error and patient discomfort.
SIB is a practical way to deliver radiotherapy in BM as
an alternative to SRS, since includes WBRT and boost
on BM in the same plan. It is therefore characterized by
logistic advantages, such as:
– a single simulation, CT-acquisition and elaboration
procedure;
– a reduction of waiting times;
– reduced dose delivery time.
All these advantages can be translated in an increased
tolerability and treatment compliance for the patient.
In addition, SIB seems to have advantages also from the
radiobiological point of view due to the possible reduction
of the phenomena of repopulation and redistribution.
In summary, this study suggests that Helical IMRT-
SIB is able to deliver slightly better plans when com-
pared to VMAT-SIB, but longer treatment times with
Helical IMRT-SRS sometimes prohibitive for patients.
In these cases SIB plans should be preferred to improve
the global outcome of treatment.
Ethical approval and consent to participate
Not applicable. Our manuscript does not contain sensi-
tive data from human patients. We performed a retro-
spective analysis on delivered treatment planning and
then we recalculated in silico new treatment planning
for each boost delivering and radiotherapy techniques,
without affection in real administered treatment. All
procedures performed in studies were in accordance
with the ethical standards of the institutional and/or na-
tional research committee and with the 1964 Helsinki
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